Clinical Trial Update: Bexarotene in Treating Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of bexarotene (brand name Targretin) in metastatic breast cancer has completed, sponsored by Ligand Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Targretin (bexarotene)

Snippet

Sponsor: Ligand Pharmaceuticals | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED